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Abstract
HPV-DNA positive (HPVDNA+) oropharyngeal squamous cell carcinoma (OSCC) has better clinical outcome than
HPV-DNA negative (HPVDNA-) OSCC. Current treatment may be unnecessarily extensive for most HPV+ OSCC, but
before de-escalation, additional markers are needed together with HPV status to better predict treatment response.
Here the influence of HLA class I/HLA class II expression was explored. Pre-treatment biopsies, from 439/484 OSCC
patients diagnosed 2000-2009 and treated curatively, were analyzed for HLA I and II expression, p16INK4a and HPV
DNA. Absent/weak as compared to high HLA class I intensity correlated to a very favorable disease-free survival
(DFS), disease-specific survival (DSS) and overall survival (OS) in HPVDNA+ OSCC, both in univariate and
multivariate analysis, while HLA class II had no impact. Notably, HPVDNA+ OSCC with absent/weak HLA class I
responded equally well when treated with induction-chemo-radiotherapy (CRT) or radiotherapy (RT) alone. In
patients with HPVDNA- OSCC, high HLA class I/class II expression correlated in general to a better clinical outcome.
p16INK4a overexpression correlated to a better clinical outcome in HPVDNA+ OSCC. Absence of HLA class I intensity in
HPVDNA+ OSCC suggests a very high survival independent of treatment and could possibly be used clinically to
select patients for randomized trials de-escalating therapy.
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Introduction
The incidence of oropharyngeal squamous cell carcinoma
(OSCC) is increasing, mainly due to a rise in human
papillomavirus (HPV) DNA positive HPV (HPVDNA+) OSCC,
suggesting an epidemic of viral-induced OSCC[1–4]. This may
be of importance for the treatment of OSCC, where tonsillar
squamous cell carcinoma (TSCC) and base of tongue
squamous carcinoma (BOTSCC) dominate[5], since HPVDNA+
tumors have a much better clinical outcome than those that are
HPV DNA negative (HPVDNA-)[6,7]. More specifically, patients
with HPVDNA+ tumors have roughly an 80% 5-year disease-
specific survival, compared those with HPVDNA- tumors, where
survival (40%) is similar to that observed in patients with other
head and neck squamous cell carcinomas (HNSCC) of similar
stages[6,8].
The fact that most HNSCC patients present with a poor
prognosis has resulted in an intensification of the oncological
treatment, resulting in a significant increase in acute and late
sequele. All patients with HPVDNA+ OSCC may not benefit from
intensified treatment, and to decrease the severe side-effects,
it has been proposed to reduce treatment for this group.
However, since a significant proportion of patients with HPVDNA
+ OSCC have a poor clinical outcome, additional predictive
markers are needed, before introducing a possible de-
escalation of treatment[9,10].
Extensive data suggest that HPVDNA+ OSCC is a different
disease-entity from HPVDNA- OSCC, and the two should be
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analyzed separately when searching for additional predictive
markers[11]. Furthermore, HPV status can be defined by
different methods, e.g. as HPVDNA+, or as HPVDNA+p16INK4a
overexpression or as sometimes by p16INK4a overexpression
alone - since p16INK4 overexpression is considered a marker of
active HPV expressing E7 mRNA[12].
In a previous smaller study, we showed that absent/weak
HLA class I expression correlated with a very favorable
outcome in HPVDNA+ TSCC, while the opposite was observed
in HPVDNA- TSCC[13]. It is possible that HLA class I
downregulation was due to that viral E5 and E7 oncoproteins
have the potential to interfere with the HLA class I presenting
machinery[14–16].
In contrast to downregulation of HLA class I expression, HLA
class II antigen expression, normally not present in epithelial
cells, can be observed in, for instance, cervical cancer[17–19].
Moreover, in vitro HLA class II expression on epithelial cells
has been shown to enhance tumor-specific immunity by
bypassing the classical antigen-presenting cell-mediated
pathway[20,21]. Moreover, HLA class II expression can be
linked to both better and worse prognoses in a variety of
malignancies, but has not been studied in OSCC[22–26].
Here, in OSCC, from a large cohort of patients, HLA class I
and II expression was analyzed in relation to HPV status and
clinical outcome. This extends our previous investigation on the
predictive value of HLA class I expression on clinical outcome.
Materials and Methods
Patients, tumor biopsies and treatment
The local cancer registry (>98% complete) was used to
identify patients with OSCC (defined as ICD-10 codes: C09,
C01.9, C05.1-8 and C10) diagnosed in the County of
Stockholm between January 2000 and October 2009 (C09 and
C01.9, for tonsillar and base of tongue cancer respectively) and
January 2000 and January 2009 (C05 and C10, for OSCC
other than tonsillar and base of tongue cancer). Eligibility
criteria were presence of available pathologically verified pre-
treatment biopsies and curative treatment with RT. Patient
records were then evaluated to verify the diagnosis and to
collect patient characteristics (Table 1).
Treatment was classified as radiotherapy (RT) (up to 68Gy in
a conventional or in an accelerated setting) or induction
chemo-RT (CRT) (Cisplatin+5Fu with/without Docetaxel – or,
as in a smaller number of cases, Cisplatin+Docetaxel
+Capecitabine – followed by conventional/accelerated RT). If
brachytherapy was added, a total dose up to 78Gy was given.
Moreover, some patients also received concomitant Cetuximab
treatment (Table 1). Before mid-2007, treatment for patients
with regional metastases also included neck dissection.
Thereafter, neck dissection was performed only in patients with
N2c or N3, and those who had remaining palpable neck nodes
after oncological treatment. Smoking data were collected and
categorized as: never smoked; stopped >15 years ago;
stopped <15 years ago and current smoker (Table 1).
A written consent was given by the patients for their
information to be stored in the hospital database and to be
used for research. The study was conducted according to
ethical permissions 2005/431-31/4, 2005/1330-32 and
2009/1278-31/4 from the Regional Ethical Committee at
Karolinska Institutet.
HPV DNA analysis
DNA was extracted from 30µm paraffin-embedded pre-
treatment biopsy slices, as previously described[2]. Presence
of HPV DNA was analyzed using a bead-based multiplex assay
on a MagPix instrument (Luminex Corporation), as described
elsewhere[27].
Immunohistochemistry
HLA class I heavy chains were detected using the mouse
monoclonal antibodies (mAb) HCA-2 and HC-10, (HCA-2
recognizes most HLA-A and HC-10 most HLA-B and -C heavy
chains, with some overlaps) and HLA class II antigens using
mAb LGII-612.14 (recognizes HLA-DR –DQ and DP, but not
other HLA class II antigens). These antibodies, kind gifts from
Dr Soldano Ferrone, University of Pittsburgh, Cancer Institute,
PA, USA, have been extensively described elsewhere[28–31].
Expression of p16INK4a was detected using the mAb p16INKA4a
(clone: JC8, dilution 1:100, Santa Cruz Biotech, California,
U.S.A.).
Staining, with negative and positive controls, was performed
as previously described[13] and evaluated blind by two
investigators (AN and EA). In the case of disagreement a
consensus was made. Fractions of HLA class I and II positive
cells were evaluated semi-quantitatively as five grades: 0 (0%),
1 (1-25%), 2 (26-50%), 3 (51-75%), and 4 (76-100%). Staining
intensity was also evaluated and scored on a three-tier scale
as absent, weak and strong staining[13]. Expression of p16INK4a
was scored as positive (strong nuclear staining in >70% cells)
or as negative staining. (Figure S1 shows examples of staining
for HLA class I and p16INK4a).
Statistical analysis
The Chi square test was used for categorical data and the
student t-test to compare mean values.
Survival was measured in years from the date of diagnosis
until a defined event or until 3 years after diagnosis, when
patients were censored. An event was defined as death due to
any cause (overall survival, OS), death with OSCC present
(disease-specific survival, DSS) or recurrence in OSCC
(disease-free survival, DFS). Patients who died without a
documented OSCC present were considered as a censored
observation in DSS and patients who died without a prior
recurrence were censored at day 0 in DFS. The Kaplan-Meier
estimator was used to estimate DFS, DSS and OS. Differences
in survival were tested using the log-rank test. The Cox
proportional hazards model was used to calculate the
unadjusted and adjusted hazard ratios (HR).
All tests were performed two-sided at the 5% significance
level. All calculations were performed using SAS software (ver.
9.3, SAS Institute Inc., Cary, NC, USA).
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Table 1. Characteristics of patients* included in the study and their tumors.
   
HPV positive OSCC patients
(N=303)
HPV negative OSCC
patients (N=136)
All OSCC patients (N=439)
  p value 
Patient characteristics   N % N % N %  
Age Mean (years)  60  63  61  <0.001
 Median (years)  59  62  60   
 Range (years)  30-90  30-87  30-90   
 Inter-quartile range (years)  53-66  56-71  54-67   
Diagnose malignant neoplasm of the base of tongue(C01.9) 75 25% 28 21% 103 24% <0.001
 malignant neoplasm of the palate(C05.0-9) 7 2.3% 15 11% 22 5.0%  
 malignant neoplasm of the tonsil (C09.0-9) 217 72% 66 49% 283 65%  
 malignant neoplasm of the oropharynx(C10.0-9) 4 1.3% 27 20% 31 7.1%  
Sex female  80 26% 39 29% 119 27% 0.64
 male  223 74% 97 71% 320 73%  
Tumour differentiation poor  198 65% 78 57% 276 63% 0.052
 moderate  89 29% 45 33% 134 31%  
 well  7 2.3% 10 7.4% 17 3.9%  
 undefined  9 3.0% 3 2.2% 12 2.7%  
Tumour size T1  75 25% 19 14% 94 21% 0.009
 T2  110 36% 43 32% 153 35%  
 T3  57 19% 40 29% 97 22%  
 T4  61 20% 34 25% 95 22%  
Nodal disease N0  49 16% 54 40% 103 23% <0.001
 N1  70 23% 17 13% 87 20%  
 N2a  47 16% 13 10% 60 14%  
 N2b  96 32% 21 15% 117 27%  
 N2c  29 10% 22 16% 51 12%  
 N3  10 3.3% 8 5.9% 18 4.1%  
 NX  2 0.66% 1 0.74% 3 0.68%  
Distant metastasis M0  297 98.0% 132 97% 429 97.7% 0.17
 M1  3 1.0% 0 0% 3 0.68%  
 MX  3 1.0% 4 2.9% 7 1.6%  
Tumour Stage I  4 1.3% 10 7.4% 14 3.2% 0.009
 II  22 7.3% 14 10% 36 8.2%  
 III  76 25% 33 24% 109 25%  
 IVa  183 60% 68 50% 251 57%  
 IVb  15 5.0% 11 8.1% 26 5.9%  
 IVc  3 1.0% 0 0.0% 3 0.68%  
Treatment Induction chemotherapyand radiation conventional 146 48% 85 63% 231 53% 0.18
  accelerated 57 19% 15 11% 72 16%  
 Radiation conventional 28 9.2% 9 6.6% 37 8.4%  
  accelerated 72 24% 27 20% 99 23%  
Brachytherapy boost Not administered  240 79% 102 75.0% 342 78% 0.32
 Administered  63 21% 34 25.0% 97 22%  
Concomittant
Cetuximab Not administered  265 87% 125 92% 390 89% 0.19
 Administered  38 13% 11 8.1% 49 11%  
Smoking Never  98 32% 14 10% 112 26% <0.001
 Former (>15 years ago)  54 18% 7 5.1% 61 14%  
 Former (<15 years ago)  52 17% 13 10% 65 15%  
 Current upon diagnosis  99 33% 102 75% 201 46%  
p16INK4a expression positive  246 81% 15 11% 261 59% <0.001
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Results
Patients, HPV and tumor characteristics
In total, 551 patients were identified with OSCC, and 439
fulfilled the inclusion criteria e.g. treated with curative intent and
with available diagnostic pre-treatment biopsies (Table 1),
while 45 patients treated with curative intent without available
biopsies were excluded from the analysis (Table S1).
Altogether, 303/439 (69%) of the OSCC were HPVDNA+, with
the majority of HPVDNA+ cases being represented by TSCC
(217/283, 77%) and BOTSCC (75/103, 73%) respectively.
Tumors in the soft palate and oropharynx harbored HPVDNA
more rarely - 7/22 (32%) and 4/31 (13%) respectively (Table 1).
Overexpression of p16INK4a was significantly more frequently
observed in HPVDNA+ (p<0.001) compared to HPVDNA- OSCC.
However, when analyzed in the different sub-sites separately,
significant correlations between HPVDNA and p16INK4a were only
observed in TSCC and BOTSCC (both p<0.001).
Patients with HPVDNA+ OSSC, when compared to patients
with HPVDNA- OSCC, were younger (p<0.001); more likely
never to have smoked (p<0.001); presented significantly more
frequently with smaller tumors (p=0.009); had greater nodal
disease (p<0.001); and had a higher tumor stage (p=0.009)
(Table 1).
Treatment modalities were similar for patients with HPVDNA+
and HPVDNA- OSCC (Table 1).
The 45 patients treated with curative intent who were
excluded from the study due to the unavailability of biopsies
only differed from the group included in the analysis in terms of
treatment, where administration of conventional RT dominated
(Table S1).
HLA class I and II expression and HPV in OSCC
In HPVDNA+ OSCC, the fraction and intensity of HLA class I
expressing cells were generally lower, and the fraction and
intensity of HLA class II expressing cells were higher compared
to HPVDNA- OSCC (Table 2).
HPV and survival in OSCC patients
Patients with HPVDNA+ OSCC had a significantly better DFS,
DSS and OS than patients with HPVDNA- OSCC (p<0.001 by
the log-rank test for all three end-points). The 3-year DFS in
the HPVDNA+ and the HPVDNA- groups was 88% (95% CI 84-91)
Table 2. HLA class I and II exptression in HPV DNA
positive and HPV DNA negative oropharyngeal squamous
cell carcinoma patients.
  
HPVDNA positive
status
HPVDNA negative
status  
  N % N % p-value§
Intensity of
HCA-2 positive
cells
absent 101 33% 24 18% 0.001
 weak 60 20% 45 33%  
 strong 142 47% 67 49%  
Fraction of HCA-2
positive cells absent 101 33% 24 18% 0.009
 1-25% 33 11% 14 10%  
 26-50% 24 8% 16 12%  
 51-75% 33 11% 14 10%  
 76-100% 112 37% 68 50%  
Intensity of HC-10
positive cells absent 60 20% 9 7% 0.001
 weak 73 24% 33 24%  
 strong 170 56% 94 69%  
Fraction of HC-10
positive cells absent 60 20% 9 7% 0.001
 1-25% 24 8% 7 5%  
 26-50% 16 5% 4 3%  
 51-75% 39 13% 15 11%  
 76-100% 164 54% 101 74%  
Intensity of
LGII-612.14
positive cells
absent 100 33% 82 60% <0.001
 weak 29 10% 11 8%  
 strong 174 57% 43 32%  
Fraction of
LGII-612.14
positive cells
absent 100 33% 82 60% <0.001
 1-25% 26 9% 10 7%  
 26-50% 23 8% 7 5%  
 51-75% 34 11% 12 9%  
 76-100% 120 40% 25 18%  
§ Chi-square test
doi: 10.1371/journal.pone.0077025.t002
Table 1 (continued).
   
HPV positive OSCC patients
(N=303)
HPV negative OSCC
patients (N=136)
All OSCC patients (N=439)
  p value 
Patient characteristics   N % N % N %  
 negative  57 19% 121 89% 178 41%  
*Number of patients with OSCC according to the local Cancer Registry, and after reviewing patients' records: 551 patients   
Number of patients excluded, not meeting the incusion criteria, due to:        
 Patients without pre-treamtent biopsies available   45 patients   
 Patients with palliative treatment only    63 patients   
 Patients with surgical treatment only    4 patients   
doi: 10.1371/journal.pone.0077025.t001
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and 66% (95% CI 56-75) respectively. Corresponding numbers
in the two groups for DSS were: 88% (95% CI 84-91) and 59%
(95% CI 49-67) respectively; and for OS 84% (95% CI 79-88)
and 51% (95% CI 42-59) respectively.
In a multivariate analysis, including sex, age, tumor
localization and stage, HPVDNA+ status was still a highly
significant determinant of survival. The unadjusted hazards
ratios for DFS were: 0.30 (95% CI 0.19-0.48); for DSS: 0.23
(95% CI 0.15-0.36) and for OS: 0.26 (95% CI 0.18-0.37)
respectively. The corresponding adjusted hazard ratios for DFS
were: 0.30 (95% CI 0.18-0.50); for DSS: 0.23 (95% CI
0.15-0.36); and for OS: 0.27 (95% CI 0.18-0.39) respectively.
HLA class I and clinical outcome in patients with
HPVDNA+ and HPVDNA- OSCC
Since HPVDNA+ OSCC and HPVDNA- OSCC are regarded as
two different disease entities, they have been analyzed
separately[2,6–8,11,13].
In HPVDNA+ OSCC, absent or a weak HLA class I intensity
was in general more often associated with a favorable clinical
outcome than strong HLA class I intensity (Table 3). Likewise,
if the fraction of positive cells was analyzed, patients with
HPVDNA+ OSCC with low staining presented a better DFS, DSS
and OS than HPVDNA+ patients with high staining (Table 3).
Only the intensity data are presented in more detail.
In a Kaplan-Meier analysis, patients with HPVDNA+ OSCC
with an absence of HLA class I had a better DFS, DSS and OS
than those with tumors with strong HLA class I expression.
Patients with HPVDNA+ OSCC with weak HLA class I
expression presented an intermediate survival (Figure 1).
More specifically, the 3-year DFS rates in the groups with
absent, weak or strong staining for HCA-2 were 97% (95% CI
90-99); 91% (95% CI 80-96); and 81% (95% CI 73-86)
respectively (Figure 1A). Corresponding numbers for DSS in
the three staining categories (absent, weak and strong) were
92% (95% CI 84-96); 93% (95% CI 82-97) and 83% (95% CI
76-89) respectively (Figure 1B); and for OS 91% (95% CI
83-95); 88% (95% CI 77-94) and 77% (95% CI 70-83)
respectively (Figure 1C).
A similar pattern was obtained for HC-10 staining, with 3-
year DFS in the absent, weak and strong staining groups of
100%; 89% (95% CI 79-95); and 83% (95% CI 76-88)
respectively (Figure 1D). Corresponding numbers for DSS in
the three staining categories (absent, weak and strong) were
98% (95% CI 89-100); 89% (95% CI 79-94) and 84% (95% CI
77-89) respectively (Figure 1E), and for OS these were 95%
(95% CI 85-98); 88% (95% CI 78-94) and 78% (95% CI 71-84)
respectively (Figure 1F).
In a multivariate analysis, including sex, age, tumor site and
stage, absence of HLA class I intensity was still a determinant
of favorable clinical outcome in the HPVDNA+ group (Table 3).
However, this was not the case when analyzing only fractions
of positive cells (Table 3).
In the HPVDNA- group, the opposite trend was generally
observed. The absence of HLA class I staining corresponded
to a worse clinical outcome (Table S2 and Figure S2).
HLA class I, treatment and clinical outcome in patients
with HPVDNA+ OSCC
The possible impact of HLA class I expression on treatment
with RT vs. CRT was examined, although the two groups were
not entirely homogenous since different RT and CRT regimens
were used. Furthermore, there was most probably a selection
bias for more patients with a poor clinical status receiving only
RT than CRT. A Kaplan-Meier analysis was performed for
DFS, DSS and OS and presented for DSS in Figure 2.
In HPVDNA+ OSCC with absence of HLA class I, there were
no significant differences in DFS, DSS (Figure 2A and 2D) and
OS in patients treated with CRT compared to RT: HCA-2:
p=0.91, p=0.94 and p= 0.68 respectively; and HC-10: p=1.00,
p=0.46 and p=0.20 respectively.
Similarly, there were no differences in DFS, DSS (Figure 2B
and 2E) and OS when the same analysis was performed in
HPVDNA+ OSCC with weak HLA class I intensity for HCA-2:
p=0.15, p=0.88 and p=1.0 respectively; and HC-10: p=0.27,
p=0.82 and p=0.99 respectively.
However, patients with HPVDNA+ OSCC with strong HLA
class I intensity had a significantly better DFS, DSS and OS if
treated with CRT than with RT as shown for HCA-2: p=0.030,
p=0.007 (Figure 2C), p=0.002 respectively; and HC-10:
p=0.036, p=0.014 (Figure 2F) and p=0.007 respectively.
HLA class II and clinical outcome in patients with
HPVDNA+ and HPVDNA- OSCC
HLA class II expression did not influence the clinical outcome
in HPVDNA+ OSCC (Table 3). In HPVDNA- OSCC strong HLA
class II staining indicated a better clinical outcome (DFS:
p=0.064; DSS: p=0.020; OS: p=0.004) (data not shown and
Table S2).
p16INK4a, HPVDNA status, HLA class I and prognosis
Overexpression of p16INK4a correlated to a favorable DFS,
DSS and OS irrespective of HPV status (log rank: p<0.0001 in
all endpoints), and in HPVDNA+ OSCC (DFS: p=0.055; DSS:
p<0.001; OS: p<0.001).
In a subgroup analysis, patients with HPVDNA+ OSCC with an
absence of or weak HLA class I intensity staining generally
presented a better clinical outcome than those with OSCC with
a strong tumor HLA class I expression, irrespectively of p16INK4a
status. More specifically, in HPVDNA+ and p16INK4a positive
OSCC, absence of or weak HLA class I intensity was an
indicator of a favorable DFS (Figure 3A and C), DSS and OS,
as compared to strong HLA intensity staining. However,
statistical significance was only obtained for DFS. The
generally higher p-values were most likely due to an overall
better survival for HPVDNA+ p16INK4a positive OSCC with strong
HLA class I intensity.
A similar pattern was obtained for HPVDNA+ and p16INK4a
negative OSCC, with absence of or weak HLA class I tumor
intensity staining being an indicator of a favorable DFS (Figure
3B and D), DSS and OS, as compared to strong HLA intensity
staining. However, due to the limited number of patients
statistical significance was only obtained for DSS and OS, but
not in DFS.
HLA Class I and II and HPV in Oropharyngeal Cancer
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Figure 1.  Kaplan-Meier curves for disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS) in
patients with HPV positive oropharyngeal squamous cell carcinoma (OSCC) with known HLA class I expression.  (A) DFS
stratified for HCA-2 intensity, (B) DSS stratified for HCA-2 intensity, (C) OS stratified for HCA-2 intensity, (D) DFS stratified for
HC-10 intensity, (E) DSS stratified for HC-10 intensity, and (F) OS stratified for HC-10 intensity. HPVDNA+ OSCC with absent HLA
class I intensity had a significant better clinical outcome than tumors with strong HLA class I intensity, while weak intensity staining
presented an intermediate survival (HCA-2: DFS p<0.001; DSS p=0.060; OS p=0.022; HC-10: DFS p=0.003, DSS p=0.021 and OS
p=0.009, with the log-rank test). Notably, the difference observed in the HCA-2 DSS analysis did not reach significance, although
the trend was similar.
doi: 10.1371/journal.pone.0077025.g001
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Figure 2.  Survival presented with Kaplan-Meier curves, and analyzed using the logrank test, for disease-specific survival
(DSS) in patients with HPV-positive oropharyngeal squamous cell carcinoma (HPVDNA+ OSCC) with known HLA class I
intensity and different treatment regimes.  (A) DSS in HPVDNA+ OSCC with absent HCA-2 intensity stratified for radiotherapy
(RT) and induction chemotherapy-RT, (B) DSS in HPVDNA+ OSCC with weak HCA-2 intensity stratified for radiotherapy (RT) and
induction chemotherapy-RT, (C) DSS in HPVDNA+ OSCC with strong HCA-2 intensity stratified for radiotherapy (RT) and induction
chemotherapy-RT, (D) DSS in HPVDNA+ OSCC with absent HC-10 intensity stratified for radiotherapy (RT) and induction
chemotherapy-RT, (E) DSS in HPVDNA+ OSCC with weak HC-10 intensity stratified for radiotherapy (RT) and induction
chemotherapy-RT, (F) DSS in HPVDNA+ OSCC with strong HC-10 intensity stratified for radiotherapy (RT) and induction
chemotherapy-RT.
doi: 10.1371/journal.pone.0077025.g002
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Discussion
In this large cohort of OSCC patients, a significant correlation
between absent/weak HLA class I expression and a very
favorable clinical outcome was observed in HPVDNA+ OSCC,
independent of treatment regime. In contrast, HPVDNA+ OSCC
with strong HLA class I intensity presented a worse clinical
outcome. HLA class II expression was not correlated to clinical
outcome in patients with HPVDNA+ OSCC. In HPVDNA- OSCC,
both a strong HLA class I and a strong class II expression were
associated with a better clinical outcome.
The correlation between absent HLA class I expression and
favorable clinical outcome in patients with HPVDNA+ OSCC was
in line with our previous results in TSCC[13], although the
underlying mechanism for the favorable outcome is still
unknown. Nonetheless, as also stated previously in the pilot
study [13], the very suppression of HLA expression may be due
to biologically very active HPV in the tumors, where E5 and E7
are known to have the potential to downregulate HLA
expression. Such tumors are most likely sensitive to RT, since
no additive survival effect was observed between RT and CRT
in patients with absent/weak HLA class I staining in HPVDNA+
OSCC. However, whether these tumors are truly more
sensitive to RT, or perhaps upregulate HLA class I expression
during RT, as has been shown in other malignancies[32,33],
and are targeted by the immune response, are issues that
need further investigation. Other explanations may include
immune selection against tumors with strong initial HLA class I
expression. Alternatively, these tumors could be more sensitive
to NK-cells as has been shown for example for breast cancer
or cervical cancer with low HLA expression [34,35].
Figure 3.  Survival presented with Kaplan-Meier curves, and analyzed using the logrank test, for disease-free survival
(DFS), in patients with HPV-positive (HPVDNA+) and p16INK4a positive/negative oropharyngeal squamous cell carcinoma
(OSCC).  (A) DFS in HPVDNA+ p16INK4a positive OSCC stratified for HCA-2 intensity (p=0.016), (B) DFS in HPVDNA+ p16INK4a negative
OSCC stratified for HCA-2 intensity (p=0.072), (C) DFS in HPVDNA+ p16INK4a positive OSCC stratified for HC-10 intensity (p=0.024),
(D) DFS in HPVDNA+ p16INK4a negative OSCC stratified for HC-10 intensity (p=0.083).
doi: 10.1371/journal.pone.0077025.g003
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Patients with HPVDNA+ OSCC and strong HLA class I
intensity may or may not have benefited from CRT, since we
assume that there was a selection bias for patients with a
worse clinical condition to receive only RT. Further studies are
necessary to clarify the role of CRT for this group.
p16INK4a expression was also evaluated and showed, in line
with previous reports[36–39], correlation to HPVDNA status and
favorable clinical outcome. When patients were stratified for
HPV status, overexpression of p16INK4a was a prognostic
marker in HPVDNA+ OSCC. However, whether this correlation is
due to our HPV assay sensitivity or to an actual prognostic
impact remains to be elucidated.
Interestingly, in HPVDNA+ OSCC absence of HLA class I
resulted in a very favorable clinical outcome irrespective of
p16INK4a overexpression. We suggest that these tumors are
indeed caused by HPV, even in those lacking 16INK4a
overexpression, since lack of p16INK4a overexpression may be
caused by other means than the absence of E7 expression,
such as methylation of the 16INK4a promoter[40].
The correlation between strong HLA class I expression and
favorable clinical outcome in HPVDNA- OSCC is in line with
previous studies by others and ourselves in other
malignancies, including HNSCC and HPVDNA- TSCC, and is
often explained by enhanced immune recognition[13].,[41–43]
Upregulated HLA class II expression correlated to a
favorable clinical outcome in HPVDNA- OSCC similar to what
has been shown for some[22,24–26], but not all
malignancies[23]. Furthermore, upregulation of HLA class II
antigens did not correlate to absence of/weak expression of
HLA class I in HPVDNA+ OSCC (data not shown), which could
have indicated that absence of HLA class I was compensated
for by immune recognition in the context of HLA class II
antigens.
The main limitation of this study is the retrospective
observational design. Moreover, it is likely that there was a
selection bias for patients with a poorer clinical condition to
more frequently receive only RT. Nevertheless, our OSCC
cohort is one of the largest analyzed, and of the patients
treated with the intention to cure >90% were included.
Furthermore, irrespective of treatment with CRT or RT and a
possible bias in selection of treatment, patients with HPVDNA+
OSCC with an absence of, or weak HLA class I expression
presented very high DFS, DSS and OS.
In conclusion, patients with HPVDNA+ OSCC and absence of
HLA class I had a very high survival, independent of treatment
regime. Subsequently, a prospective experimental study should
be initiated to better examine absence of HLA class I
expression as a marker for de-escalation of oncological
treatment.
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